Tab Application Banner
  • Users Online: 683
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Reader Login
Export selected to
Reference Manager
Medlars Format
RefWorks Format
BibTex Format
  Access statistics : Table of Contents
   2012| March  | Volume 7 | Issue 1  
    Online since July 28, 2016

  Archives   Previous Issue   Next Issue   Most popular articles   Most cited articles
Hide all abstracts  Show selected abstracts  Export selected to
  Viewed PDF Cited
Evaluation of clinical pharmacist mediated education and counselling of systemic lupus erythematosus patients in tertiary care hospital
MS Ganachari, Syeda Atiya Almas
March 2012, 7(1):7-12
Objectives: To assess the knowledge of systemic lupus erythematosus (SLE) patients before and after clinical pharmacist's education and compare the same with the control group. Methods: In this study done on patients with SLE, the test group patients were provided with education regarding SLE and its management including lifestyle modifications, via the distribution of patient information leaflets (PILs), while the control group were continued with conventional therapy. Validated knowledge assessment questionnaire was administered at baseline, first follow-up and final (second) follow-up to assess the medication knowledge of SLE patients. The Modified Morisky Scale (MMS) was used to assess the adherence at the final follow-up to study the influence of education. Results: Forty-five patients completed the 2 months follow-up study out of 50 enrolled patients. A significant (P < 0.001) improvement in the medication knowledge scores and medication adherence was seen in test group compared to the control group. The reasons for non-compliance included patients forgetfulness, high cost of medi- cations, patients lack of access to hospital/drug store, lack of family support/motivation, fear of side effects, and fear of becoming dependent on treatment. Conclusion: The finding of this study showed that a well-structured SLE patient counselling by clinical pharmacist's intervention will result in improved medication knowledge and better medication adherence.
[ABSTRACT]   Full text not available  [PDF]  [Mobile Full text]  [EPub] [CITATIONS]
  2,044 203 8
Alopecia in lupus: Experience from a tertiary referral centre
Alakes Kumar Kole, Rammohan Roy
March 2012, 7(1):3-6
Background: Alopecia is a non-specific cutaneous manifestation of lupus and seen in 45-54% of lupus patients at any time during the disease process. Lupus and alopecia often go hand in hand and produce significant psychoso- cial impact. Objectives: To study the different patterns of alopecia in lupus, relationship to disease activity and its psychosocial impact. Methods: Lupus patients attending the Rheumatology and Dermatology Clinics in the North Bengal Medical College and Hospital were evaluated with special reference to different patterns of alopecia, relationship with disease activity and its impact on lifestyle. Results: A total of 50 lupus patients were studied. Forty patients had alopecia during the study period, whereas 10 patients had alopecia at the time of presentation. Different patterns of alopecia observed were telogen effluvium in 20 cases, 'lupus hair' in 10 cases, scarring alopecia (associated with discoid lesions) in seven and alopecia areata in five cases, but alopecia totalis was not detected. 'Lupus hair' was associated with high disease activity and 15 patients had impaired quality of life because of recurrent alopecia and scarring. Conclusion: Alopecia is a less serious disease manifestation in lupus, though it can produce a significant psycho- social impact in the quality of life.
[ABSTRACT]   Full text not available  [PDF]  [Mobile Full text]  [EPub]
  1,764 175 -
Common anti-infective prophylaxis and vaccinations in autoimmune inflammatory rheumatic diseases
Vineeta Shobha
March 2012, 7(1):21-28
An exhilarating era for autoimmune inflammatory rheumatic diseases (AIRD) has arrived; new therapeutics are emerging that not only control symptoms, but also may allow a chance for remission. However, enthusiasm must be tempered with judicious caution as gaps in our knowledge remain regarding long-term safety data especially with respect to new onset infections and reactivation of latent infections such as tuberculosis (TB). Chronic vigilance and appropriate anti-infective measures such as trimethoprim/sulphamethaxozole and TB chemoprophylaxis should be instituted whenever indicated to minimise risk. Vaccination is an appropriate choice to prevent substantial number of these infections. In this context, pneumococcal and influenza vaccines are the best evaluated and are recom- mended by standard vaccination guidelines by most of experts. Some studies have found mildly impaired immune responses to vaccines among patients receiving long-term immunosuppressive therapy and tumour necrosis factor (TNF) antagonists, but post vaccination antibody titres are frequently adequate to provide shield for the majority of immunised individuals. The accumulated data on the safety and effectiveness of vaccines warrant immunisation with the majority of vaccines for patients with AIRD with the exception of live vaccines. In India, however there is a con- cern about futility of influenza vaccine, as it is feared that the serotypes targeted in this vaccine may not be the prevailing in our geographic area. Vaccination status assessment as soon as diagnosis of any of AIRDs is estab- lished and updating to appropriate vaccination status should compulsorily be implemented in daily clinical practice by rheumatologists.
[ABSTRACT]   Full text not available  [PDF]  [Mobile Full text]  [EPub] [CITATIONS]
  1,687 148 2
Biomarkers in systemic lupus erythematosus: Do they make the mark?
Varun Dhir
March 2012, 7(1):13-20
Biomarkers are indicators of biological processes. In lupus we especially require activity biomarkers to look at pre- dicting flares, differentiating damage from activity, and assessing response to treatment. There are numerous mol- ecules that have been evaluated for these purposes, but studies suffer from limitations of design, statistical rigor, and outcome measure. The best biomarker remains the oldest one, double-standard deoxyribonucleic acid (dsDNA) and has many longitudinal studies to back it, and shows the ability to predict renal flares. Apart from this anti-C1q, cell-bound complement activation products and urinary molecules-chemokines and neutrophil gelatinase-associated lipocalin (NGAL)-are promising. The interferon signature has not lived up to its promise; however, microRNA (miRNA) signature is newly coming up as a marker of activity. Even if we do come up with better biomarkers, there is lack of clarity on issues of socio-economic impact as well as psychological impact of frequent testing for biomarkers.
[ABSTRACT]   Full text not available  [PDF]  [Mobile Full text]  [EPub]
  1,675 148 -
Rheumatology quiz
Vivek Arya, Varun Dhir
March 2012, 7(1):35-35
Full text not available  [PDF]  [Mobile Full text]  [EPub]
  1,317 210 -
CHOPping the biologics?!
Arun Shrivastava, Dhanita Khanna
March 2012, 7(1):29-34
Full text not available  [PDF]  [Mobile Full text]  [EPub]
  1,387 113 -
Drugs don't work if you don't take them: Emerging role of the pharmacist counsellor in patient compliance
Adesh Govind Mathur
March 2012, 7(1):1-2
Full text not available  [PDF]  [Mobile Full text]  [EPub]
  1,363 133 -
What is your diagnosis?: Bilateral ankle swelling in a renal-transplant recipient
Prasanta Padhan, Debabrata Padhy, Bikash Agrawala, Ajit Biswal, Samiran Adhikary
March 2012, 7(1):42-43
Full text not available  [PDF]  [Mobile Full text]  [EPub]
  1,251 126 -
What is your diagnosis?: A patient with low backache and paraparesis
Rajesh Verma, Puneet Kumar, Mani Gupta
March 2012, 7(1):39-41
Full text not available  [PDF]  [Mobile Full text]  [EPub]
  1,235 140 -
International publications of interest from India: (December 2011-February 2012)
Vivek Arya
March 2012, 7(1):36-38
Full text not available  [PDF]  [Mobile Full text]  [EPub]
  1,272 97 -
What is your diagnosis?: A rare cause of polyarthritis with myositis
Anil Abrol, Pradip Prajapati, Naval Mendiratta, Randeep Wadhawan, Shilajit Bhattacharya, Ashok Kumar
March 2012, 7(1):42-45
Full text not available  [PDF]  [Mobile Full text]  [EPub]
  1,218 133 -
Behçet's disease presenting as ileal perforation and a thrombosed renal artery aneurysm
Rafi Ahmed Jan, Umar Hafiz Khan, Kursheed Alam Wani, Rouf Wani, Gul Javead, Sonaullah Shah, Showkat Mufti, Syed Mudasir, Fayaz Ahmed Sofi, Parviaz A Koul
March 2012, 7(1):60-61
Full text not available  [PDF]  [Mobile Full text]  [EPub]
  816 104 -
Nasal polyposis: A rare presenting feature of limited Wegner's granulomatosis
Partha Sarathi Karmakar, Subrata Basu, Parasar Ghosh, Sumantra Dutta, Ranjit Bari, Kaushik Basu, Alakendu Ghosh
March 2012, 7(1):54-55
Full text not available  [PDF]  [Mobile Full text]  [EPub]
  805 108 -
Idiopathic thrombocytopaenic purpura in a first-degree relative of a patient with multiple sclerosis
S Muthamil Selvan, V Anitha, PN Vinoth, J Julius Xavier Scott
March 2012, 7(1):56-57
Full text not available  [PDF]  [Mobile Full text]  [EPub]
  781 86 -
Subclinical aortitis in a case of polychondritis
Sivasami Kartik, Darshan Singh Bhakuni, Krishnan Shanmuganandan, Mahesh Singh Chauhan
March 2012, 7(1):46-46
Full text not available  [PDF]  [Mobile Full text]  [EPub] [CITATIONS]
  745 116 1
Rheumatology reviews: January-March 2012
Sukhbir Uppal
March 2012, 7(1):47-53
Full text not available  [PDF]  [Mobile Full text]  [EPub]
  705 110 -
Oral citrullination-A neoteric link in autoimmunity
Lalitha T Arunachalam
March 2012, 7(1):59-60
Full text not available  [PDF]  [Mobile Full text]  [EPub]
  724 89 -
A faceless nemesis: Systemic sclerosis sine scleroderma
Dharam Pal Bansal, Dilip Gude, Guruprasad Padsalgi, Saurabh Patle
March 2012, 7(1):57-58
Full text not available  [PDF]  [Mobile Full text]  [EPub]
  713 99 -